Articles On Immutep (ASX:IMM)
Title | Source | Codes | Date |
---|---|---|---|
Encouraging results for Immutep’s cancer therapies
Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt provides an update on the company's pipeline of clinical trials, focusing on results in head and neck cancer, lung cancer and breast cancer. Manny Anton: Hello. I'm Manny Ant... |
ShareCafe | IMM | 3 days ago |
ASX Health Winners February: Law of attrition applies but biotech is a long term game; Nyrada up 5x last month
ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr... |
Stockhead | IMM | 3 weeks ago |
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs
Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks There were a couple of big news from the world of biotec... |
Stockhead | IMM | 1 month ago |
Immutep (ASX:IMM) – Webinar Presentation
Marc Voigt, Executive Director & CEO, Immutep (ASX:IMM) is a clinical-stage biotechnology company at the forefront of developing novel LAG-3 immunotherapy for cancer and autoimmune diseases. |
ShareCafe | IMM | 1 month ago |
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners
Xi and Biden set to agree on restricting fentanyl Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks China’s President Xi is expected... |
Stockhead | IMM | 4 months ago |
Healthcare stocks can drive healthy returns
At the $240 million Perennial Better Future Trust, healthcare stocks are a critical component of our ESG-focused portfolio. These stocks, many of which have global reach, have the potential to generate attractive returns while shaping a bet... |
Rask Media | IMM | 4 months ago |
ScoPo’s (actually Wilkie’s) Powerplays: Yoga = chill. Fact. And ASX health stocks up for second week
ASX health stocks rise in past five days and outpace broader markets Blue chip ResMed slips as US FDA approves weight loss drug Clinical stage immuno-oncology small cap Immutep gains 160% Morgans healthcare and life sciences expert Iain... |
Stockhead | IMM | 4 months ago |
Stocks of the Hour: Sunstone Metals, Immutep, European Metals Holdings, QX Resources
To register for Friday's webinar click here. Sunstone Metals (ASX:STM) announced the initial Exploration Target shows Limon is on track to be a substantial gold-silver deposit. In response, Sunstone Managing Director Malcolm Norris commen... |
ShareCafe | IMM | 4 months ago |
Stocks of the Hour: Sunstone Metals, Immutep, European Metals Holdings, QX Resources
09 Nov 2023 - A snapshot of the stocks on the move, featuring Sunstone Metals (ASX:STM), Immutep (ASX:IMM, NASDAQ:IMMP), European Metals Holdings (ASX:EMH & AIM:EMH) and QX Resourc… |
FNN | IMM | 4 months ago |
Market Highlights: Oil sheds another 2pc, the most shorted stocks on ASX, and small caps to watch today
ASX to rise despite a muted session on Wall Street Oil plunged another 2pc overnight, possibly signalling a recession S&P released the 10 most shorted stocks on the ASX Aussie shares are poised to open higher on Thursday as Wall Str... |
Stockhead | IMM | 4 months ago |
Immutep announces the completion of key stage of AIPAC-003 trial in metastatic breast cancer
Immutep (ASX:IMM) has announced that the open-label safety lead-in of its integrated AIPAC-003 Phase 2/3 trial evaluating 90mg of eftilagimod alpha in combination with paclitaxel has been completed with no safety or tolerability iss... |
BiotechDispatch | IMM | 4 months ago |
ASX closes 0.28% higher ahead of RBA’s cash rate decision
The ASX experienced a subdued Monday session, with its benchmark index nearing 7000 points for the first time in over two weeks, anticipating the Reserve Bank's impending cash rate decision. Australia's central bank is anticipated to raise... |
ShareCafe | IMM | 4 months ago |
ASX up 0.37% at noon: RBA’s likely hike
The Australian sharemarket began the week with a slight upward movement, as investors remained watchful for the Reserve Bank's cash rate decision scheduled for Tuesday, with both bond and equity traders exercising caution in their approach.... |
ShareCafe | IMM | 4 months ago |
Stocks of the Hour: Whispir, QX Resources, Immutep, Magnis Energy Tech
06 Nov 2023 - A snapshot of the stocks on the move, featuring Whispir (ASX:WSP), QX Resources (ASX:QXR), Immutep (ASX:IMM) and Magnis Energy Technologies (ASX:MNS). |
FNN | IMM | 4 months ago |
Stocks of the Hour: Whispir, QX Resources, Immutep, Magnis Energy Tech
Soprano Design Australia Pty Ltd today announces its intention to make an off-market takeover bid for all the ordinary shares in Whispir Limited (ASX: WSP) for $0.48 cash per share. The all cash offer price of $0.48 is best and final and... |
ShareCafe | IMM | 4 months ago |
ASX up 1.1% at noon following Wall Streets gains
The Australian stock market has surged around midday, buoyed by the positive performance on Wall Street, amid growing optimism that the Federal Reserve might have concluded its series of interest rate hikes. At noon, the S&P/ASX 200 is... |
ShareCafe | IMM | 4 months ago |
Immutep reports new biomarker data from TACTI-002 phase II trial
Immutep (ASX:IMM) announces new biomarker data from its phase II TACTI-002 trial for patients with previously untreated unresectable or metastatic NSCLC Data from blood samples reveals unique immune system stimulation when using efti in... |
themarketherald.com.au | IMM | 4 months ago |
Stocks of the Hour: Findi, Immutep, ImpediMed
To register for today's webinar click here. Findi (ASX:FND) has extended the existing State Bank of India contract until 30 September 2024. Commenting on the SBI contract extension, Findi Chairman Mr Nicholas Smedley said: “The SBI contra... |
ShareCafe | IMM | 4 months ago |
ASX Today: Stocks to watch on Friday
Welcome to the end of the trading week. ASX futures were up 1.23 per cent (85pts) at 8:30 am AEDT. This implies the ASX will rise after a second green night in the US on the back of a Fed pause. The S&P 500 had its best day since Apr... |
themarketherald.com.au | IMM | 4 months ago |
Stocks of the Hour: Findi, Immutep, ImpediMed
03 Nov 2023 - A snapshot of the stocks on the move, featuring Findi (ASX:FND), Immutep (ASX:IMM) and ImpediMed (ASX:IPD). |
FNN | IMM | 4 months ago |
Immutep (ASX:IMM) reports 71.4% response rate for lung cancer therapy
Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses progress of the company's drug candidates, highlighting promising data from the 2023 ESMO Congress. Paul Sanger: I'm Paul Sanger for the Finance News Network, and... |
ShareCafe | IMM | 4 months ago |
Q&A: Immutep’s CEO on improving lung cancer survival, and where to next after trial success
Cancer is a nasty disease and the leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths according to World Health Organisation data. Companies and medical facilities worldwide are wor... |
Stockhead | IMM | 5 months ago |
ASX closes 0.19% higher as Energy stocks get a boost from rising oil prices
On Tuesday, energy and mining stocks drove gains in the Australian sharemarket. Energy stocks benefited from the rise in oil prices, with West Texas Intermediate trading around $86 per barrel. The avoidance of a Gaza invasion by Tel Aviv te... |
ShareCafe | IMM | 5 months ago |
TMH Market Close: Bitcoin surges as investors anticipate ETF launch
The ASX200 lifted nearly 0.2 of a per cent by the end of the day’s session, with materials taking a late run to gain .8 of a per cent. Energy also added almost half a per cent. Cryptocurrency Bitcoin has also jumped almost 10 per cent... |
themarketherald.com.au | IMM | 5 months ago |
Stocks of the Hour: Immutep, Empire Energy, Lincoln Minerals
24 Oct 2023 - A snapshot of the stocks on the move, featuring Immutep (ASX:IMM), Empire Energy (ASX:EEG) and Lincoln Minerals (ASX:LML). |
FNN | IMM | 5 months ago |
Stocks of the Hour: Immutep, Empire Energy, Lincoln Minerals
Immutep (ASX:IMM) has reported promising clinical data from the INSIGHT-003 trial at the ESMO Congress 2023. In response, Immutep CSO, commented, “the compelling data that our proprietary MHC Class II agonist has generated in combination... |
ShareCafe | IMM | 5 months ago |
ASX currently up 0.22%: Energy is best performing sector
The spotlight is on RBA Chief Michele Bullock's speech scheduled for 7pm AEDT at the Global Markets Conference hosted by CBA in Sydney. At noon, the S&P/ASX 200 is 0.22 per cent higher at 6,859.30. The SPI futures are pointing to a rise... |
ShareCafe | IMM | 5 months ago |
Australian share market turns red for 2023
The Australian stock market has given up all of the gains that it had made in 2023, with the benchmark S&P/ASX 200 (INDEXASX: XJO) losing 56.6 points, or 0.8%, on Monday to 6,844.1, with resources weakness the major culprit. That puts t... |
Rask Media | IMM | 5 months ago |
Positive efficacy result for Immutep’s 'efti' in combination with MSD's pembrolizumab
Australian company Immutep (ASX:IMM) has announced positive data from a trial of its LAG-3 immunotherapy, eftilagimod alpha, in combination with MSD's KEYTRUDA (pembrolizumab). |
BiotechDispatch | IMM | 5 months ago |
TMH Market Close: ASX200 stoops to 100-day low
The ASX200 closed down .8 of a per cent to a new 100-day low. Energy took the biggest hit – losing three per cent and materials wasn’t much better, shedding 2.3 per cent – while healthcare bucked the trend, adding 1.5 per cent. In the... |
themarketherald.com.au | IMM | 5 months ago |
Closing Bell: It certainly wasn’t cricket as Monday markets in Australia knocked right back to last year
Benchmark ASX index closes at new 12-month lows Energy and Materials the worst of 9 dipping ASX sectors on Monday Small caps led by CHM, TON On Monday Aussie markets rediscovered their nadir of the year. No real surprises, since every n... |
Stockhead | IMM | 5 months ago |
ASX closes 0.82% lower to its lowest point in a year
Australian shares closed at their lowest level in a year on Monday, following a trend set by a weaker Wall Street. This decline was driven by concerns about an escalation of the Middle East conflict, which negatively impacted investor senti... |
ShareCafe | IMM | 5 months ago |
In Case You Missed It: A bumper brain cancer trial and solid lithium hits
Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, which made announcements today. ICYMI Lead... |
Stockhead | IMM | 5 months ago |
TMH Market Update: ASX200 drops, Treasury Wine Estates rises on fast-tracked tariff review
Futures suggested the ASX200 would drop – and it’s dropped almost a per cent, with all sectors in the red, except for healthcare, which has gained nearly a per cent and consumer staples, which has added more than half a per cent. Austral... |
themarketherald.com.au | IMM | 5 months ago |
ASX Health Stocks: Chimeric leaps 65pc on Phase1A results, Immutep over 12pc on Phase 2
Chimeric Therapeutics up 50pc on Phase 1A CLTX CAR T results Immutep up 11pc on TACTI-002/KEYNOTE-798 Phase II trial results ProMedicus signs $16 million, 8-year contract with US hospital Chimeric jumps 50pc on Phase 1A results Chimeric... |
Stockhead | IMM | 5 months ago |
ASX down 0.76% at noon following Wall Street’s poor performance
At noon, the S&P/ASX 200 is 0.76 per cent lower at 6,848.40. This drop was in line with Wall Street's performance, driven by concerns about potential interest rate hikes by the Federal Reserve and worries about the escalation of the Mid... |
ShareCafe | IMM | 5 months ago |
Stocks of the Hour: Immutep, Chimeric Therapeutics, Sayona Mining
23 Oct 2023 - A snapshot of the stocks on the move, featuring Immutep (ASX:IMM; NASDAQ:IMMP), Chimeric Therapeutics (ASX:CHM) and Sayona Mining (ASX:SYA; OTCQB:SYAXF). |
FNN | IMM | 5 months ago |
Stocks of the Hour: Immutep, Chimeric Therapeutics, Sayona Mining
Immutep (ASX:IMM; NASDAQ:IMMP) announced that their Efti, a soluble LAG-3 protein, in Combination with KEYTRUDA®, generates excellent overall survival benefit in patients with metastatic non-small cell lung cancer. In response, Marc Voigt... |
ShareCafe | IMM | 5 months ago |
Immutep’s Efti and Keytruda combo shows strong survival benefits in metastatic non-small cell lung cancer
Immutep (ASX:IMM) reveals its drug Efti, in combination with Keytruda, generates significant survival benefits for those suffering from metastatic non-small cell lung cancer At lower protein PD-L1 expression, survival rates increase betw... |
themarketherald.com.au | IMM | 5 months ago |
Guess which ASX All Ords stock is jumping 16% on 'promising' results
The Immutep Ltd (ASX: IMM) share price is jumping on Monday. In morning trade, the ASX All Ords biotech stock is up 16% to 32 cents. Why is this ASX All Ords stock racing higher? Investors have been buying the company's shares today follow... |
Motley Fool | IMM | 5 months ago |
Market Highlights: Wall Street slides yet again, one mistake retirees make, and 5 ASX small caps to watch today
Aussie shares to slump once again after heavy selloff on Wall Street Traders are wary of developments in the Middle East Magnificent Seven to report their earnings this week Aussie shares are poised to open lower again after another sel... |
Stockhead | IMM | 5 months ago |
ASX Today: Stocks to watch on Monday
Welcome to the start of the week. ASX futures were down 65 points (0.95 per cent) heading into 8:30 AEDT. The US had another red session on Friday with the S&P 500 down 1.26 per cent; and the NASDAQ down 1.53 per cent. The Dow and R... |
themarketherald.com.au | IMM | 5 months ago |
Check Up: Why Goldman Sachs won’t change its ratings on 3 ASX stocks despite Ozempic-driven selloff
News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks Goldman Sachs analysts said they will make no... |
Stockhead | IMM | 5 months ago |
ASX Health Stocks: Global Health nabs Fujitsu contract, Althea generates $5.3m after property deal
Global Health announces deal with Fujitsu Australia Althea raises $5.32m in sale and leaseback deal Immutep to present data from TACTI-002 in key international forum Global Health signs with Fujitsu Global Health (ASX:GLH), a provider o... |
Stockhead | IMM | 5 months ago |
Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it
L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks Be... |
Stockhead | IMM | 6 months ago |
ASX closes 1.37% lower: Consumers becoming cautious
Consumers are becoming more cautious due to rising living costs, but UBS analysts believe this doesn’t indicate an immediate drop in spending, as they note a slight improvement in future interest rate expectations; however, sticky inflation... |
ShareCafe | IMM | 6 months ago |
ASX down 1.01% at noon after hawkish comments from the Fed
The ASX experienced continued declines at midday, with banking stocks being particularly affected. This drop was triggered by the recent hawkish statements from the US Federal Reserve. At noon, the S&P/ASX 200 is 1.01 per cent lower at... |
ShareCafe | IMM | 6 months ago |
Stocks of the Hour: Immutep, Vulcan Energy Resources, Australian Gold and Copper
21 Sep 2023 - A snapshot of the stocks on the move, featuring Immutep (ASX:IMM), Vulcan Energy Resources (ASX:VUL) and Australian Gold and Copper (ASX:AGC). |
FNN | IMM | 6 months ago |
Stocks of the Hour: Immutep, Vulcan Energy Resources, Australian Gold and Copper
Immutep (ASX:IMM; NASDAQ:IMMP) announces the regulatory authorisation of “efti”, which is the Company’s proprietary soluble LAG-3 protein, for the use in clinical trials across multiple European countries. In response, Marc Voigt, CEO of... |
ShareCafe | IMM | 6 months ago |
Market Highlights: Fed projects one more rate hike, Klaviyo’s debut, and and 5 ASX small caps to watch
ASX to open lower again on Thursday The US Fed held rates steady, but opened the door for one more hike in 2023 Klaviyo (NYSE: KVYO) made its listing debut overnight Australian shares are poised to track Wall Street and open lower once... |
Stockhead | IMM | 6 months ago |